Holaira Announces Company Name Change to Nuvaira
(Thomson Reuters ONE) -
Company Adds Shane Gleason to Executive Team
MINNEAPOLIS, June 20, 2017 (GLOBE NEWSWIRE) -- Holaira, a developer of medical
devices to treat obstructive lung diseases, today announced that it has changed
its name to Nuvaira, effective immediately. In addition, the company unveiled a
new corporate identity and website, available at www.nuvaira.com.
A photo accompanying this announcement is available
at http://www.globenewswire.com/NewsRoom/AttachmentNg/c6cd786b-e9df-4faf-ab69-
9e0030e2fb23
The company also announced the addition of Shane Gleason as chief commercial
officer. Shane is an accomplished industry executive with 18 years of healthcare
sales and operations experience, most recently as the vice president of sales
for North America at Cordis, a Cardinal Health company.
"We are proud to launch our new corporate identity as Nuvaira, which better
reflects our business strategy and development goals," said Dennis Wahr,
M.D., chief executive officer at Nuvaira. "Nuvaira represents the fusion of our
new, truly revolutionary lung denervation technology with our goal of making
breathing easier for patients with obstructive pulmonary diseases e.g., chronic
obstructive pulmonary disease (COPD) and asthma. Early clinical results for
patients with COPD show that our proprietary catheter-based system is on the way
to meeting our commitment of delivering a one-time, whole-lung solution that
helps patients and positively impacts their quality of life for the long-term.
"We are also very pleased to have Shane join our executive team as we position
the company for continued growth, multiple ongoing clinical trials and global
commercialization," continued Dr. Wahr. "He is a talented and skilled leader
with extensive worldwide sales, operations and marketing experience that
includes multiple successful product launches, significant consecutive sales
growth, and global sales implementation and development."
Shane comes to Nuvaira from Cordis, where he led North American sales
integration efforts of two sales forces and led the combined 200-plus-member
team. Before joining Cordis, Shane was vice president of U.S. sales at
TriVascular Technologies, where he built and led the U.S. sales organization to
support the launch and commercialization of their abdominal stent graft system
after leading the company's enrollment efforts in their global pivotal study.
Shane joined TriVascular from Abbott, where he held a variety of leadership
roles, including leading global and strategic marketing for Abbott's
endovascular franchise and professional education.
Shane holds an MBA from The Robert H. Smith School of Business at the University
of Maryland, and a BS in Engineering Science and Mechanics with a concentration
in Biomechanical Engineering from Virginia Polytechnic Institute and State
University.
About NUVAIRA
Nuvaira (previously known as Holaira) is a privately held company headquartered
in Minneapolis, Minn. The company is developing the Nuvaira(TM) Lung Denervation
System to address chronic obstructive pulmonary disease (COPD) by treating the
overactive airway nerves during Targeted Lung Denervation* (TLD), a minimally
invasive procedure that targets the parasympathetic innervation of the lungs(1).
This one-time bronchoscopic procedure provides an ablative therapy that opens
obstructed airways to improve breathing. Nuvaira received CE Mark approval for
its Nuvaira Lung Denervation System for use during TLD in January 2016. More
information may be found at www.Nuvaira.com.
*Targeted Lung Denervation (TLD) is currently under clinical investigation for
chronic obstructive pulmonary disease and is not yet commercially available.
NUVAIRA is a trademark of NUVAIRA, Inc.
(1) Belmonte K. Cholinergic Pathways in the Lungs and Anticholinergic Therapy
for Chronic Obstructive Pulmonary Disease. Proc Am Thor Soc 2005; 2: 297-305.
Media Contact:
Lorraine Marshall Wright
+1 (206) 605-4553
lmwright(at)Nuvaira.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nuvaira via GlobeNewswire
Datum: 20.06.2017 - 15:00 Uhr
Sprache: Deutsch
News-ID 548905
Anzahl Zeichen: 4798
contact information:
Town:
Plymouth
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 230 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Holaira Announces Company Name Change to Nuvaira"
steht unter der journalistisch-redaktionellen Verantwortung von
Nuvaira (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
